pertuzumab: clinical use

Prescribing considerations

• Confirm HER2-positive tumour status using a validated test in a suitably specialised laboratory.
• Initiate under an experienced anticancer prescriber with resuscitation facilities immediately available.
• Assess cardiac risk carefully, particularly after anthracyclines, chest radiotherapy or in the presence of conditions that impair ventricular function.
• There are limited data in severe renal impairment, hepatic impairment, adults over 75 years and patients with significant pre-existing cardiac disease.
• Dose reduction is not an established toxicity-management strategy; manage toxicity through interruption or discontinuation according to product-specific criteria.

Contraindications and cautions

• Hypersensitivity to pertuzumab or any excipient.

Monitoring

• Record the product name and batch number for biological-medicine traceability.
• Confirm baseline left ventricular ejection fraction and reassess it regularly during treatment.
• Observe closely during and after infusion for infusion-related reactions, hypersensitivity and anaphylaxis.
• Monitor for febrile neutropenia when used with myelosuppressive chemotherapy.
• Assess diarrhoea early, including hydration and electrolyte status when severe or prolonged.

Clinical pharmacology

Pertuzumab is a humanised IgG1 monoclonal antibody targeting HER2 subdomain II. It inhibits ligand-dependent HER2 heterodimerisation and downstream MAP-kinase and PI3K signalling, while also mediating antibody-dependent cellular cytotoxicity. Monoclonal antibodies are principally cleared by catabolism.

Formulation and product differences

• The selected product is a preservative-free, single-use concentrate requiring aseptic dilution for intravenous infusion. It must not be given by intravenous push or bolus or mixed with trastuzumab in the same bag.

Solution for infusion

Route: Intravenous

Strengths: 420 mg